Prospective, Open-label, Single-arm Clinical Study of Irinotecan Liposomes Combined With Cindilizumab and Lunvalatinib as Second-line Treatment for Adenocarcinoma of Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 19 Jul 2024
At a glance
- Drugs Irinotecan (Primary) ; Lenvatinib (Primary) ; Sintilimab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
Most Recent Events
- 19 Jul 2024 New trial record